Professional
Added to YB: 2026-04-27
Pitch date: 2026-03-31
RGEN [neutral]
Repligen Corporation
-0.21%
current return
Author Info
No bio for this author
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$6.6B
Pitch Price
$118.54
Price Target
N/A
Dividend
N/A
EV/EBITDA
42.54
P/E
136.74
EV/Sales
8.88
Sector
Life Sciences Tools and Services
Category
growth
Alger Mid Cap Focus Fund Portfolio Holding: Repligen Corporation
RGEN (holding update): Life sciences co providing bioprocessing tech for biologics manufacturing (mAbs, cell/gene therapy). Market leader in filtration, chromatography, process analytics. Q detracted on life sciences sector rotation & conservative low-end FY guidance. Deep customer integration + growing biologic complexity = durable long-term growth potential.
Read full article (1 min)